Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioNTech SE BNTX
$105.68
+$3.19 (3.02%)
На 18:02, 12 мая 2023
+125.57%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
24848891340.00000000
-
week52high
188.99
-
week52low
101.98
-
Revenue
17310600000
-
P/E TTM
3
-
Beta
0.21617500
-
EPS
41.32000000
-
Last Dividend
2.11100000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| SVB Leerink | Outperform | Market Perform | 13 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 июл 2022 г. |
| JP Morgan | Neutral | Neutral | 24 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| Goldman Sachs | Neutral | Neutral | 08 ноя 2022 г. |
| B of A Securities | Buy | Neutral | 15 дек 2022 г. |
| Goldman Sachs | Neutral | Neutral | 31 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
The 3 Most Undervalued Growth Stocks for Your February Buy List
InvestorPlace
06 февр 2023 г. в 06:15
Undervalued growth stocks are often overlooked by investors, they can offer significant potential for capital appreciation. One way to identify undervalued growth stocks is to look for companies with high revenue and earnings growth, but low price-to-earnings (P/E) ratios.
Better Buy: Novavax or BioNTech Stock?
The Motley Fool
04 февр 2023 г. в 08:00
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
InvestorPlace
02 февр 2023 г. в 14:19
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
Mergers and Acquisitions in 2023 Off To A Strong Start
MarketBeat
27 янв 2023 г. в 08:17
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).
Ranking The 10 Largest Biotechs By Pipeline
Seeking Alpha
11 янв 2023 г. в 12:34
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.